Latest News
AFT Pharmaceuticals latest news
Stay updated with the latest advancements and breakthroughs in the pharmaceutical industry.
November 28, 2025
AFT Pharmaceuticals SA acquires the Hospital Division of Pharma Dynamics
AFT Pharmaceuticals SA (Pty) Ltd (‘AFT SA’) announces it has successfully completed the acquisition of the Hospital Division business of Pharma Dy…
November 20, 2025
AFT delivers 10th consecutive first half revenue increase
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today reports a strong first-half performance for the six months to 30 September 2025, with revenue growing 3…
November 12, 2025
AFT Pharmaceuticals Brings Next-Generation Liposomal Collagen and Wellness Range to the U.S. Market
AFT Pharmaceuticals has launched its full Lipo-Sachets® range in the U.S., featuring advanced collagen and vitamin supplements powered by patented LI…
September 25, 2025
On track for $300m FY27 revenue; positive iron IV study result
– Sales tracking in line with $300 million FY27 revenue target – Clinical trial supports the potential patient benefits of novel iron IV development …
July 1, 2025
Combogesic IV launches in Canada; R&D progress
Q1 FY 26 HIGHLIGHTS – Maxigesic IV® (marketed as Combogesic IV®) launching in Canada this month and sales kick off for AFT Pharmaceuticals Canada a…
May 26, 2025
AFT and Hikma extend US Maxigesic Cooperation
AFT Pharmaceuticals (NZX:AFT, ASX:AFP) today announces it has extended its US Maxigesic® licensing agreement with Hikma Pharmaceuticals….
May 1, 2024
AFT Licenses Maxigesic® IV in Brazil
We are delighted to announce our partnership with Brazil’s Halex Istar, and to be exclusively responsible for distributing its Maxigesic IV in Brazi…
April 24, 2024
AFT, Massey Ventures, Gilles McIndoe to develop scar treatment
AFT collaborate with Massey Ventures and Gilles McIndoe to begin the development of a topical treatment for keloid and hypertrophic scarring….
March 5, 2024
AFT makes further progress in international markets
AFT Pharmaceuticals provides an update on recent progress it has made in international markets….
February 19, 2024
AFT updates operating profit guidance to $23m to $25m
AFT Pharmaceuticals today announces an update to guidance for the financial year to the end of March 2024 (FY24)….
February 8, 2024
MAXIGESIC® SPONSORS THE ONE NZ WARRIORS
AFT Pharmaceuticals announces Maxigesic® is the new Official Pain Relief Partner of the One New Zealand Warriors for the 2024 and 2025 NRL seasons….
February 7, 2024
Maxigesic IV launched in the United States
AFT Pharmaceuticals announces Maxigesic IV®, the patented intravenous form of its family of pain relief medicines, has today been launched in the US …
January 19, 2024
AFT further broadens R&D pipeline with new product candidate for Vulva Lichen Sclerosus
AFT Pharmaceuticals announces it has entered into a further partnership with one of its long-standing research and development partners, Belgium’s H…
January 17, 2024
AFT poised to accelerate momentum in 2024
As the new year commences, AFT Pharmaceuticals is looking forward to building upon the significant progress made during 2023. Last year we moved on fr…
January 8, 2024
AFT broadens R&D pipeline with new product candidate in Burning Mouth Syndrome
AFT Pharmaceuticals today announces that it has entered into a partnership with one of its research and development partners, Belgium’s Hyloris Phar…
November 24, 2023
AFT Pharma reports growth and global expansion
FINANCIAL RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2023…
October 18, 2023
AFT welcomes US FDA approval for sale of Maxigesic IV®
AFT Pharmaceuticals announces the US FDA has approved Maxigesic IV®, the intravenous form of its patented pain relief medicine, for sale in the US, w…
October 3, 2023
AFT appoints Andrew Lane as independent director
AFT Pharmaceuticals today announces the appointment of Andrew Lane as an independent non-executive director….
October 3, 2023
Retirement of Jon Lamb
Independent director Jon Lamb today retired from the board following his announcement at the ASM. …